noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

University of the Ozarks

University Awards 25 Degrees in Fall 2025 Commencement
Al Green

ICYMI: The Associated Press article, titled "Head of workplace rights[...]
Charlotte County, FL

Traffic Advisory - Midway Boulevard between Hariet Street and Conway[...]

Healthcare

Coya Therapeutics Inc.

12/17/2025 | Press release | Distributed by Public on 12/17/2025 07:00

Material Event (Form 8-K)

Item 8.01

Other Events.

On December 16, 2025, Coya Therapeutics, Inc. (the "Company") received a $4.2 million milestone payment under the Development and License Agreement, dated December 5, 2023 (the "DRL Development Agreement"), by and amongst the Company, Dr. Reddy's Laboratories Ltd. and its affiliate, Dr. Reddy's Laboratories SA. The milestone payment was triggered by dosing of the first patient in the Company's ALSTARS trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS), which was announced on December 9, 2025.

Coya Therapeutics Inc. published this content on December 17, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 17, 2025 at 13:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format